publication date: Nov. 30, 2015

ICT-107 Boosts Overall Survival by 10 Percent In Phase II Glioblastoma Trial

 

Updated overall survival results and immune response data a phase II trial of ICT-107 in patients with newly diagnosed glioblastoma demonstrated a survival advantage compared to the control group.

ICT-107, developed by ImmunoCellular Therapeutics Ltd., is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. The study data also show a significant association between immune response and survival, especially in HLA-A2 positive patients, the target patient population for a phase III registration trial.

The data were presented at the annual Scientific Meeting and Education Day of the Society for Neuro-Oncology in San Antonio.

The trial was a randomized, double-blind, placebo-controlled study of the safety and efficacy of ICT-107 in patients with newly diagnosed glioblastoma multiforme following resection and chemoradiation.

ICT-107 is an intradermally administered autologous immunotherapy consisting of the patient’s own dendritic cells pulsed with six synthetic tumor-associated antigens: AIM-2, MAGE-1, TRP-2, gp100, HER-2, IL-13R 2. The placebo control consisted of the patient’s unpulsed dendritic cells. All patients in the trial received standard-of-care temozolomide.

Overall survival results were analyzed at three years after the last patient enrolled. For the 124-patient intent-to-treat population, median OS was 1.6 months or 10 percent better for ICT-107 patients than control. The difference in the Kaplan-Meier survival curves for this patient population was not statistically significant.

Updated OS results for the pre-specified subgroup of HLA-A2+ patients continue to support selecting this patient population alone for a … Continue reading CCL Nov – ICT-107 Boosts Overall Survival by 10 Percent In Phase II Glioblastoma Trial

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2019 The Cancer Letter Inc.